The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.
Chronic hepatitis C
glecaprevir-pibrentasvir
real-life experience
Journal
Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
03
2023
revised:
02
06
2023
accepted:
13
06
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. GLE/PIB is an effective and tolerable treatment in patients with CHC.
Sections du résumé
Background and Aim
UNASSIGNED
The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).
Materials and Methods
UNASSIGNED
Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.
Results
UNASSIGNED
All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.
Conclusion
UNASSIGNED
GLE/PIB is an effective and tolerable treatment in patients with CHC.
Identifiants
pubmed: 37822314
doi: 10.14744/hf.2023.2023.0001
pii: hf-4-092
pmc: PMC10564251
doi:
Types de publication
Journal Article
Langues
eng
Pagination
92-96Informations de copyright
© Copyright 2023 by Hepatology Forum.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
N Engl J Med. 2020 Aug 13;383(7):608-611
pubmed: 32786185
J Viral Hepat. 2020 Jul;27(7):671-679
pubmed: 32050037
J Hepatol. 2020 Jun;72(6):1112-1121
pubmed: 32061651
Biomedicines. 2020 Apr 03;8(4):
pubmed: 32260271
J Hepatol. 2020 Mar;72(3):441-449
pubmed: 31682879
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Swiss Med Wkly. 2021 Jan 19;151:w20399
pubmed: 33516161
Infect Dis Ther. 2021 Dec;10(4):2203-2222
pubmed: 34125405
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767
pubmed: 30245064
Lancet Infect Dis. 2017 Oct;17(10):1062-1068
pubmed: 28818546
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Clin Med. 2021 Nov 10;10(22):
pubmed: 34830518
J Hepatol. 2018 Aug;69(2):293-300
pubmed: 29551706
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Clin Microbiol Infect. 2015 Nov;21(11):1020-6
pubmed: 26163105
Lancet Infect Dis. 2016 Dec;16(12):1385-1398
pubmed: 27665254
J Clin Med. 2021 Jul 25;10(15):
pubmed: 34362064
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Adv Ther. 2020 Sep;37(9):4033-4042
pubmed: 32754824
Turk J Gastroenterol. 2020 Dec;31(12):883-893
pubmed: 33626001
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28193664
Int J Med Sci. 2006;3(2):47-52
pubmed: 16614742
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101596
pubmed: 33610022